Risks

Interest coverage near 1.1x leaves limited cushion if rates stay elevated, but Lilly’s low leverage is materially safer than highly levered pharma peers.

A current ratio of 1.27x suggests only moderate liquidity headroom, though it remains stronger than peers that rely more heavily on short-term funding.

Negative net debt to EBITDA indicates net cash positioning, reducing refinancing risk versus peers with meaningful gross debt and supporting resilience through demand volatility.

Working-capital efficiency is strong, but the near-zero inventory buffer can amplify supply disruptions more than peers with larger safety stocks.

Because the company’s balance sheet is structurally conservative, macro financing risk is a secondary constraint rather than a primary threat versus large-cap pharmaceutical peers.

Opportunities

Net cash and minimal debt provide flexibility to fund launches and capacity expansion faster than leveraged peers, supporting growth capture in high-demand markets.

Strong cash conversion cycle efficiency improves internal funding capacity, giving Lilly more room than peers to reinvest in commercialization and pipeline execution.

Low leverage reduces earnings sensitivity to financing costs, preserving margin durability versus peers with heavier interest burdens in a higher-rate environment.

Tight working-capital management can support faster cash generation than peers, strengthening optionality for strategic investment during periods of elevated product demand.

Overall Score

Lilly’s net-cash balance sheet and efficient cash generation create strong peer-relative resilience and funding flexibility, while only modest liquidity and coverage constraints temper the upside.